Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Hormone Therapy Response Associated with Signaling Activity in Circulating Cancer Cells

By BiotechDaily International staff writers
Posted on 07 Nov 2012
A study monitoring hormone receptor activity in tumor cells from patients being treated for resistant metastatic prostate cancer has found that such monitoring may be useful for indicating which patients will be more likely to respond well to continued therapy.

Treatments that inhibit the androgen receptor (AR) pathway, androgen-deprivation therapy (ADT), are initially highly effective in most patients with metastatic prostate cancer (MPC); however, since cancer cells often develop resistance, secondary hormonal therapies are being tested to suppress androgen receptor reactivation. There are variable responses to such secondary therapy, but no reliable biomarkers are available to guide the use of AR pathway inhibitors in treating resistant MPC. A collaborative team of researchers led by Prof. Daniel A. Haber, MD, PhD, and director of the Massachusetts General Hospital Cancer Center (Charlestown, MA, USA) have now established a method using microfluidic capture of circulating tumor cells (CTCs) to isolate cancer cells from the blood of patients with MPC and single-cell immunofluorescence analysis to measure androgen receptor signaling activity in the individual CTCs.

Monitoring was performed on CTCs from patients with castration-resistant prostate cancer (CRPC), before and after therapeutic interventions. Prior to the initiation of ADT, the AR pathway was turned on in most CTCs from newly diagnosed patients. Initiation of first-line ADT induced a profound switch from “AR-on” to “AR-off” CTCs. In patients whose cancer had become resistant after initially responding well to androgen-deprivation therapy, the CTCs population became highly variable - some CTCs were AR-on, others AR-off, and still others had characteristics of both AR-on and AR-off. The presence of cells with a mixed AR signaling pattern was associated with an adverse treatment outcome. In addition, in patients treated with a new drug, abiraterone acetate, which achieves more complete androgen deprivation than earlier treatments, an increased percentage of AR-on CTCs despite abiraterone treatment was associated with decreased overall survival.

The assay may provide a valuable marker to help target such treatments to patients more likely to respond to second-line therapies. "This study is a proof of principle that it is possible to monitor, in patients with metastatic prostate cancer, the androgen receptor signaling pathway in real time, repeatedly and noninvasively," said Prof. Haber. He added, "As more drugs are developed that target the different pathways that drive the recurrence of metastatic prostate cancer in different patients, it will become essential to know which drug and which pathway is relevant in each patient. Our assay will be an effective way to interrogate the tumor and follow it during the course of treatment to monitor therapy response and the emergence of drug resistance."

The study was published early online October 23, 2012, in Cancer Discovery, a journal of the American Association for Cancer Research.

Related Links:
Massachusetts General Hospital Cancer Center
American Association for Cancer Research


Channels

Genomics/Proteomics

view channel
Image: The photo shows a mouse pancreatic islet as seen by light microscopy. Beta cells can be recognized by the green insulin staining. Glucagon is labeled in red and the nuclei in blue (Photo courtesy of Wikimedia Commons).

Regenerative Potential Is a Trait of Mature Tissues, Not an Innate Feature of Newly Born Cells

Diabetes researchers have found that the ability of insulin-producing beta cells to replicate and respond to elevated glucose concentrations is absent in very young animals and does not appear until after weaning.... Read more

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.